The successful candidate will break news on an industry that has suffered a major political loss in the United States and is bracing for new federal efforts to bring down the cost of prescription medicines.
This reporter would shed light on the commercial strategies of leading industry players, with a broad view on how new medicines in development will impact companies, investors, patients and providers.
At the same time, the candidate will report on how big pharma companies are turning to deals and new business opportunities after having benefited tremendously from developing vaccines and treatments critical to alleviating the COVID-19 pandemic.
The reporter would demonstrate a track record of deep source development and show how they would cultivate a roster of sources among pharmaceutical and biotech executives, government health officials and industry investors. The preferred location for the role is New York.
About the Role
As our U.S. Pharmaceutical Industry Reporter, you will:
About You
To be our U.S. Pharmaceutical Industry Reporter, you will likely have:
Please note, the deadline for applications is Friday 14th October 2022.
To apply, go here.
PCWorld executive editor Gordon Mah Ung, a tireless journalist we once described as a founding father…
CNBC senior vice president Dan Colarusso sent out the following on Monday: Before this year comes to…
Business Insider editor in chief Jamie Heller sent out the following on Monday: I'm excited to share…
Former CoinDesk editorial staffer Michael McSweeney writes about the recent happenings at the cryptocurrency news site, where…
Manas Pratap Singh, finance editor for LinkedIn News Europe, has left for a new opportunity…
Washington Post executive editor Matt Murray sent out the following on Friday: Dear All, Over the last…